Page last updated: 2024-08-22

platinum and Minimal Disease, Residual

platinum has been researched along with Minimal Disease, Residual in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Bulleri, A; Cosio, S; Frey, J; Gadducci, A; Mezzapesa, F; Miccoli, M; Neri, E; Simonetti, E; Tintori, R1
Ferrari, F; Gadducci, A; Landoni, F; Peiretti, M; Perrone, F; Sartori, E; Tana, R1
Achatz, MI; Baiocchi, G; da Costa, AA; Guimarães, AP; Mantoan, H; Saito, A; Sanches, S; Valadares, CV1
Altınbaş, SK; Boran, N; Celik, B; Hızlı, D; Köse, MF; Turan, T; Yılmaz, S1
Horwich, A; Stenning, S1
Fujiwara, K1

Trials

1 trial(s) available for platinum and Minimal Disease, Residual

ArticleYear
Initial chemotherapy for stage II testicular non-seminoma.
    World journal of urology, 1994, Volume: 12, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confidence Intervals; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasm, Residual; Norway; Orchiectomy; Platinum; Prognosis; Remission Induction; Retroperitoneal Neoplasms; Retrospective Studies; Survival Rate; Teratoma; Testicular Neoplasms; United Kingdom

1994

Other Studies

5 other study(ies) available for platinum and Minimal Disease, Residual

ArticleYear
Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study.
    Anticancer research, 2022, Volume: 42, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Italy; Middle Aged; Muscle, Skeletal; Neoplasm, Residual; Ovarian Neoplasms; Ovariectomy; Platinum; Prognosis; Progression-Free Survival; Retrospective Studies; Sarcopenia; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

2022
Analysis of failures and clinical outcome of advanced epithelial ovarian cancer in patients with microscopic residual disease at second-look reassessment following primary cytoreductive surgery and first-line platinum-based chemotherapy.
    European journal of gynaecological oncology, 2013, Volume: 34, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Retrospective Studies; Second-Look Surgery; Treatment Failure; Treatment Outcome

2013
Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Risk Factors; Survival Rate

2015
Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer.
    European journal of obstetrics, gynecology, and reproductive biology, 2012, Volume: 163, Issue:1

    Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome

2012
Intraperitoneal chemotherapy and intraperitoneal washing cytology in management of ovarian cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2

    Topics: Antineoplastic Agents; Carboplatin; Female; Humans; Infusions, Parenteral; Neoplasm, Residual; Ovarian Neoplasms; Peritoneal Lavage; Platinum; Reoperation; Survival Analysis

2000